Fulcrum Therapeutics (NASDAQ:FULC) shares rose over 5% after BofA upgraded ratings to Neutral, citing likelihood of success ...

The biotech will now suspend development of a drug prospect that Sanofi acquired partial rights to just four months ago.

Sanofi has added to its rare disease pipeline by licensing an antibody-RNA conjugate (ARC) for facioscapulohumeral muscular dystrophy (FSHD), a genetic muscle disorder, from US biotech miRecule.

Fulcrum Therapeutics (NASDAQ:FULC) lost ~70% premarket Thursday after its lead program for protein kinase inhibitor, ...

Losmapimod failed to show an improvement in relative surface area (RSA), a measure of reachable workspace (RWS), versus placebo at week 48 ―― ...

Fulcrum Therapeutics Inc. (NASDAQ:FULC) stock is trading lower on Thursday after the company released data from the Phase 3 ...

BofA Securities has upgraded Fulcrum Therapeutics (NASDAQ:FULC) ahead of the company’s phase 3 losmapimod readout, expected ...

Fulcrum is developing another pipeline candidate, pociredir, in an early-stage study for treating patients with sickle cell ...

In a report released on September 11, Joseph Schwartz from Leerink Partners reiterated a Buy rating on Fulcrum Therapeutics (FULC – ...

Shares of Fulcrum Therapeutics plummeted after the company said a trial evaluating losmapimod as a treatment for facioscapulohumeral muscular dystrophy missed its primary endpoint. The stock was down ...

The S&P 500's 2024 rally continued in July as second-quarter GDP growth numbers exceeded expectations. Investors also expect Federal Reserve rate cuts are now just around the corner. The S&P 500 ...